Novartis to acquire Regulus Therapeutics for $1.7bn.

Novartis, a company specializing in global healthcare solutions, agreed to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company, for $1.7bn. "We are excited to combine with Novartis to potentially bring farabursen to patients living with ADPKD, who currently have limited treatment options. Novartis' established global development and commercial capabilities will enable this important new medicine to reach patients if approved. I am proud of the work that our team at Regulus has achieved in advancing this important new therapy and would like to thank all of the patients, investigators, and the ADPKD community in moving our program forward to this important milestone," Jay Hagan, Regulus Therapeutics CEO.